General Updates

INDGN/SE/2026-27/31 17 July 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Business Responsibility and Sustainability Report for Financial Year 2025-26 Pursuant to Regulations 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 (“SEBI Listing Regulations”), please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) for financial year 2025-26, The BRSR also forms an integral part of the Annual Report of Indegene Limited for financial year 2025-26. The above information will be made available on the website of the Company: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer M. No. A21609 Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Indegene Limited BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT At Indegene, sustainability and responsible business practices continue to remain integral to the way we operate and create value. Over the past year, we have strengthened our commitment to building a future-ready healthcare ecosystem by further embedding Environmental, Social, and Governance (“ESG”) considerations into our strategic priorities, operational processes, and decision-making frameworks. As a tech-native, life sciences specialist, we remain focused on orchestrating the path from commercialization strategy through activation while ensuring that our growth is responsible, inclusive, and aligned with long- term sustainability objectives. Following the publication of our first Business Responsibility and Sustainability Report (“BRSR”) for FY 2024–25, we are pleased to present our subsequent disclosure for FY 2025–26. This report reflects our continued commitment to transparency, consistency, and accountability in ESG reporting. It builds upon the foundations established in the previous year, with enhanced disclosures, strengthened internal processes, and improved alignment of ESG priorities with business strategy. Structured in accordance with the nine principles of the National Guidelines on Responsible Business Conduct (“NGRBC”) and compliant with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this report provides a comprehensive overview of our ESG performance and progress. It highlights how we are operationalising our commitments across governance, environmental stewardship, and social responsibility, while also responding to evolving stakeholder expectations and regulatory developments. Through this BRSR, we aim to offer our stakeholders a clear and credible view of our sustainability journey, demonstrating not only continuity in our commitments but also measurable progress in key areas. As we move forward, we remain committed to strengthening our ESG practices, driving innovation in sustainable healthcare delivery, and creating enduring value for all our stakeholders. SECTION A: GENERAL DISCLOSURES I. Details of the Listed Entity 1 Corporate Identity Number (CIN) of the Listed Entity L73100KA1998PLC102040 2 Name of the Listed Entity Indegene Limited (“the Company”) 3 Year of incorporation 1998 4 Registered office address Aspen G4, 3rd Floor, Manyata Embassy Business Park Outer Ring Road, Nagavara, Bangalore, Karnataka, India – 560 045 5 Corporate address Aspen G4, 3rd Floor, Manyata Embassy Business Park Outer Ring Road, Nagavara, Bangalore, Karnataka, India – 560 045 6 E-mail compliance.officer@indegene.com 7 Telephone +91 8046744567, +91 8046447777 8 Website https://www.indegene.com 9 Financial year for which reporting is being done FY 2025 – 2026 10 Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”) 11 Paid-up Capital INR 481802708 12 Name and contact details (telephone, email address) of the Srishti Ramesh Kaushik person who may be contacted in case of any queries on the compliance.officer@indegene.com BRSR +91 8046744567, +91 8046447777 13 Reporting boundary - Are the disclosures under this report made Disclosures made in this report are on a standalone on a standalone basis (i.e. only for the entity) or on a consolidated basis and pertain only to Indegene Limited basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together) 14 Name of assurance provider TÜV SÜD South Asia Pvt. Ltd. 15 Type of assurance obtained Reasonable Assurance as per ISAE 3000 Indegene Limited Annual Report 2025-26 II. Products/Services 16. Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1 Other Professional, Scientific & Other Professional, Scientific & 100% Technical activities Technical activities 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. No. Product/Service NIC Code % of total Turnover contributed 1 Service M 749 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 0 6 27 International 0 21 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 5 International (No. of Countries) 58 b. What is the contribution of exports as a percentage of the total turnover of the entity? The contribution of exports as a percentage of the total turnover of the Company is: FY 2025-2026 FY 2024-2025 Remarks 98.47% 98.27% (Including Inter-Company revenue) c. A brief on types of customers The Company provides AI-embedded commercialization services for the life sciences industry, which includes biopharmaceutical, emerging biotech, and medical devices companies. Biopharmaceutical segment comprises companies that discover, develop, manufacture, and sell drugs (chemical and biological-based) to treat, vaccinate, or alleviate symptoms of medical conditions or diseases. Medical devices segment comprises companies involved in the research, development, production, and sale of systems and devices of medical applications, i.e., to treat or diagnose diseases or medical conditions. Emerging biotech segment comprises companies that derive their products from the extraction or manipulation of living organisms and are in the process of developing products and technologies that improve our lives and the health of our planet. Indegene Limited IV. Employees 20. Details as of 31 March 2026: a. Employees and workers* (including differently abled): S. Particulars Total (A) Male Female No. No. (B) % (B / A) No. (C) % (C / A) Employees 1 Permanent (D) 4679 2598 55.52% 2081 44.48% 2 Other than Permanent (E) 488 299 61.27% 189 38.73% 3 Total Employees (D+E) 5167 2897 56.07% 2270 43.93% Differently abled Employees No. (B) % (B / A) No. (C) % (C / A) 1 Permanent (D) 8 5 62.50% 3 37.50% 2 Other than Permanent (E) 0 0 0.00% 0 0.00% 3 Total Employees (D+E) 8 5 62.50% 3 37.50% • *All our workforce is categorized as ‘Employees’, and none as ‘Workers’. • Total Employees (D+E) includes differently abled employees. • Trainees and Interns are considered as Permanent Employees. 21. Participation/Inclusion/Representation of women Particulars Total (A) No. and percentage of Females No. (B) % (B / A) Board of Directors 11 2 18.18% Key Management Personnel 4 1 25.00% 22. Turnover rate for permanent employees and workers FY 2025 [Showing first 8,000 characters — download PDF for full document]